Paul Resnick serves as Vice President and Chief Business Officer of MabVax Therapeutics.  He has over 20 years of industry experience spanning large pharmaceutical and public and private biotechnology companies encompassing corporate development, product development, licensing and collaboration. From January 2013 to March 2016, Dr. Resnick was Senior Vice President, for Juventas Therapeutics where he was responsible for business and commercial strategy and working with executive management overseeing clinical development and financial and business strategies. From January 2008 to January 2012 he was Vice President, Business Development and member of the executive management team for Intellikine, Inc. (acquired by Takeda Pharmaceuticals), responsible for managing alliances and leading the business development strategy that resulted in securing an acquisition by Takeda Pharmaceuticals. Earlier in his career Dr. Resnick held Director and Senior Director positions at Pfizer, Rinat Neuroscience (acquired by Pfizer), Intermune, Inc. and Roche Pharmaceuticals.  Dr. Resnick earned a Doctor of Medicine from The Medical College of Wisconsin and a Master of Business Administration from The Wharton School of the University of Pennsylvania.